Chemopreventive effect of peroxisome proliferator-activated receptor γ on gastric carcinogenesis in mice

Cancer Research

Volumn 65, Issue 11, 2005, Pages 4769-4774

  Lu, Jie ^a,d   Imamura, Kazuhiro ^a   Nomura, Sachiyo ^a   Mafune, Ken Ichi ^a   Nakajima, Atsushi ^e   Kadowaki, Takashi ^b   Kubota, Naoto ^c   Terauchi, Yasuo ^b   Ishii, Genichiro ^d   Ochiai, Atsushi ^d   Esumi, Hiroyasu ^d   Kaminishi, Michio ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c UNIVERSITY OF TOKYO   (Japan)

^d NATIONAL CANCER CENTER   (Japan)

^e YOKOHAMA CITY UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

METHYLNITROSOUREA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; TROGLITAZONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CHEMOPROPHYLAXIS; CONTROLLED STUDY; DRUG INHIBITION; HETEROZYGOSITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; STOMACH CANCER; WILD TYPE;

ANIMALS; ANTICARCINOGENIC AGENTS; CARCINOGENS; CHROMANS; FEMALE; GASTRIC MUCOSA; LIGANDS; MALE; METHYLNITROSOUREA; MICE; MICE, KNOCKOUT; PPAR GAMMA; STOMACH NEOPLASMS; THIAZOLIDINEDIONES;

EID: 21144439861     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2293     Document Type: Article

References (48)

1. Green S, Tugwood JD, Issemann I. The molecular mechanism of peroxisome proliferator action: a model for species differences and mechanistic risk assessment. Toxicol Lett 1992;64 Spec:131-9.
2. Bardot O, Aldridge TC, Latruffe N, Green S. PPAR-RXR heterodimer activates a peroxisome proliferater response element upstream of the bifunctional enzyme gene. Biochem Biophys Res Commun 1993; 192:37-45.
3. Keller H, Mahfoudi A, Dreyer C, et al. Peroxisome proliferator-activated receptors and lipid metabolism, Ann N Y Acad Sci 1993;684:157-73.
4. Gimble JM, Pighetti GM, Lerner MR, et al. Expression of peroxisome proliferator activated receptor mRNA in normal and tumorigenic rodent mammary glands. Biochem Biophys Res Commun 1998;253:813-7.
5. Mansen A, Guardiola-Diaz H, Rafter J, Branting C, Gustafsson JA. Expression of the peroxisome proliferator-activated receptor (PPAR) In the mouse colonic mucosa. Biochem Biophys Res Commun 1996;222:844-51.
6. McGowan SE, Jackson SK, Doro MM, Olson PJ. Peroxisome proliferators alter lipid acquisition and elastin gene expression in neonatal rat lung fibroblasts, Am J Physiol 1997;273:1249-57.
7. Huin C, Corriveau L, Bianchi A, et al. Differential expression of peroxisome proliferator-activated receptors (PPARs) in the developing human fetal digestive tract. J Histochem Cytochem 2000;48:603-11.
8. Elstner E, Muller C, Koshizuka K, et al. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998;95:8806-11.
9. Tontonoz P, Singer S, Forman BM, et al. Terminal differentiation of human liposarcoma cells induced by ligands for peroxisome proliferator-activated receptor gamma and the retinoid X receptor. Proc Natl Acad Sci U S A 1997;94:237-41.
10. Rumi MA, Sato H, Ishihara S, et al. Peroxisome proliferator-activated receptor gamma Ugand-induced growth inhibition of human hepatocellular carcinoma. Br J Cancer 2001;84:1640-7.
11. Heaney AP, Fernando M, Melmed S, PPAR-gamma receptor ligands: novel therapy for pituitary adenomas. J Clin Invest 2003;111:1381-8.
12. Ohta K. Endo T, Haraguchi K, Hershman JM. Onaya T. Ligands for peroxisome proliferator-activated receptor gamma inhibit growth and induce apoptosis of human papillary thyroid carcinoma cells. J Clin Endocrinol Metab 2001;86:2170-7.
13. Badawi AF, Badr MZ. Chemoprevention of breast cancer by targeting cyclooxygenase-2 and peroxisome proliferator-activated receptor-gamma (Review). Int J Oncol 2002;20:1109-22.
14. Brown PH, Lippman SM. Chemoprevention of breast cancer. Breast Cancer Res Treat 2000;62:1-17.
15. Kopelovich L, Fay JR, Glazer RI, Crowell JA. Peroxisome proliferator-activated receptor modulators as potential chemopreventive agents. Mol Cancer Ther 2002;1:357-63.
16. Li J, Lv Y, Dong X, Jin Z. Pioglitazone, a peroxisome proliferators-activated receptor gamma ligand, inhibits dimethylhydrazine (DMH) induced aberrant crypt foci in rats. Beijing Da Xue Xue Bao 2003;35:537-9.
17. Lefebvre AM, Chen I, Desreumaux P, et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice, Nat Med 1998;4:1053-7.
18. Saez E, Tontonoz P, Nelson MC, et al. Activators of the nuclear receptor PPARγ enhance colon polyp formation. Nat Med 1998;4:1058-61.
19. Wang M, Wise SC, Leff T, Su TZ, Troglitazone, an antidiabetic agent, inhibits cholesterol biosynthesis through a mechanism independent of peroxisome proliferator-activated receptor-gamma. Diabetes 1999; 48:254-60.
20. Castrillo A, Mojena M, Hortelano S. Bosca L, Peroxisome prolifetator-activated receptor-gamma-independent inhibition of macrophage activation by the non-thiazolidinedione agonist L-796,449. Comparison with the effects of 15-deoxy-δ(12,14)-prostaglandin J(2). J Biol Chem 2001;276:34082-8.
21. Palakurthi SS, Aktas H, Grubissich LM, Mortensen RM, Halperin JA. Anticancer effects of thiazolidinediones are independent of peroxisome proliferator-activated receptor gamma and mediated by inhibition of translation initiation. Cancer Res 2001;61:6213-8.
22. Okano H, Shiraki K, Inoue H, et al. 15-deoxy-δ-12-14-PGJ2 regulates apoptosis induction and nuclear factor-κB activation via a peroxisome proliferator-activated receptor-gamma-independent mechanism in hepato-cellular carcinoma Lab Invest 2003;83:1529-39.
23. Weber SM, Scarim AL, Corbett JA. PPAR{γ} is not required for the inhibitory actions of PGJ2 on cytokine signaling in pancreatic {β}-cells. Am J Physiol Endocrinol Metab 2004;286:E329-36.
24. Roder DM. The epidemiology of gastric cancer. Gastric Cancer 2002;5 Suppl 1:5-11.
25. Parkin DM, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: Globocan 2000. Int J Cancer 2001; 94:153-6.
26. Eguchi T, Fujli M, Takayama T. Mortality for gastric cancer in elderly patients. J Surg Oncol 2003;84:132-6.
27. Correa P. Chemoprevention of gastric cancer: has the time come? J Clin Oncol 2003;21:270-1.
28. Kakizoe T, Chemoprevention of cancer: focusing on clinical trials. Jpn J Clin Oncol 2003;33:421-2.
29. Wong JE, Ito Y, Correa P, et al. Therapeutic strategies in gastric cancer. J Clin Oncol 2003;21:267-9.
30. Takahashi N, Okumura T, Motomura W, Fujimoto Y, Kawabata I, Kohgo Y. Activation of PPARγ inhibits cell growth and induces apoptosis in human gastric cancer cells. FEBS Lett 1999;455:135-9.
31. Sato H, Ishihara S, Kawashima K, et al. Expression of peroxisome proliferator-activated receptor (PPAR)-gamma in gastric cancer and inhibitory effects of PPARγ agonists. Br J Cancer 2000;83:1394-400.
32. 1 arrest by p27(Kip1)26 induction that is mediated by inhibition of proteasome in human gastric cancer cells. Jpn J Cancer Res 2002;93: 774-82.
33. Chen YX, Zhong XY, Qin YF, Bing W, He LZ. 15d-PGJ2 inhibits cell growth and induces apoptosis of MCG-803 human gastric cancer cell line. World J Gastroenterol 2003;9:2149-53.
34. Nagamine M, Okumura T, Tanno S, et al. PPAR gamma ligand-induced apoptosis through a p53-dependent mechanism in human gastric cancer cells. Cancer Sci 2003;94:338-43.
35. Kubota N, Terauchi Y, Miki H, et al. PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 1999;4:597-609.
36. Nakajima A, Wada K, Mild H, et al. Endogenous PPAR gamma mediates anti-inflammatory activity in murine ischemia-reperfuslon injury. Gastroenterology 2001;120: 460-9.
37. Yamaohika T, Nakanishi H. Inada K, et al. N-methyl-N-nitrosourea concentration-dependent, rather than total intake-dependent, induction of adenocarcinomas in the glandular stomach of BALB/c mice. Jpn J Cancer Res 1998;89:386-91.
38. Sporn MB, Suh N, Mangelsdorf DJ, Prospects for prevention and treatment of cancer with selective PPARγ modulators (SPARMs). Trends Mol Med 2001; 7:395-400.
39. Saez E, Rosenfeld J, Livolsi A, et al. PPAR gamma signaling exacerbates mammary gland tumor development, Genes Dev 2004;18:528-40.
40. Clay CE, Namen AM, Atsumi G, et al. Magnitude of peroxisome proliferator-activated receptor-gamma activation is associated with important and seemingly opposite biological responses in breast cancer cells. J Investig Med 2001;49:413-20.
41. Clay CE. Monjazeb A, Thorburn J, Chilton FH, High KP. 15-Deoxy-δ12,14-prostaglandin J2-induced apoptosis does not require PPARγ in breast cancer cells. J Lipid Res 2002;43:1818-28.
42. Place AE, Suh N, Williams CR, et al. The novel synthetic triterpenoid. CDDO-imidazolide, inhibits inflammatory response and tumor growth in vivo. Clin Cancer Res 2003;9:2798-806.
43. Christopher JN, Michung Y. Jerrold M, et al. PPAR gamma influences susceptibility to DMBA-induced mammary, ovarian and skin carcinogenesis. Carcinogenesis 2004;25:1747-55.
44. Mueller E, Sarraf P, Tontonoz P, et al. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998;1:465-70.
45. Wang C, Pattabiraman N, Zhou JN, et al. Cyclin D1 repression of peroxisome proliferator-activated receptor gamma expression and transactivation. Mol Cell Biol 2003;23:6159-73.
46. Bogazzi F, Ultimieri F, Raggi F, et al. Changes in the expression of the peroxisome proliferator-activated receptor gamma gene in the colonic polyps and colonic mucosa of 27 acromegalic patients. J Clin Endocrinol Metab 2003;88:3938-42.
47. Badawi AF, Eldeen MB, Liu Y, Ross EA, Badr MZ. Inhibition of rat mammary gland carcinogenesis by simultaneous targeting of cyclooxygenase-2 and peroxisome proliferator-activated receptor gamma. Cancer Res 2004;64:1181-9.
48. Wada K, Nakajima A, Takahashi H, et al. Protective effect of endogenous PPAR{γ} against acute gastric mucosal lesions associated with ischemia-reperfusion. Am J Physiol Gastrointest Liver Physiol 2004;287:452-8.